Want to see CRBP full AI Analyst Report?
CRBP Stock Chart & Stats
$11.31
-$0.15(-1.61%)
At close: 4:00 PM EDT
$11.31
-$0.15(-1.61%)
Day’s Range― - ―
52-Week Range$7.12 - $20.56
Previous CloseN/A
Volume172.71K
Average Volume (3M)451.40K
Market Cap
$222.04M
Enterprise Value$68.37
Total Cash (Recent Filing)$117.94M
Total Debt (Recent Filing)$4.26M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Nov 10, 2026EPS Estimate
-1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.19
Shares Outstanding19,341,293
10 Day Avg. Volume651,975
30 Day Avg. Volume451,405
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$38.00Price Target Upside235.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-5.36
Revenue Forecast (FY)$1.67M
Bulls Say, Bears Say
Bulls Say
Liquidity RunwayThe projected runway gives Corbus time to advance late-stage programs without immediate financing pressure. This supports continued clinical execution and preserves flexibility while the company seeks regulatory or business-development milestones.
CRB-701 Phase 3 ProgressFDA clearance moves CRB-701 into a registrational study, materially advancing its path toward potential commercialization. Successful development could create a future product-based revenue stream and validate Corbus’s oncology strategy.
Clinical And Leadership CapabilitiesProgress across CRB-913 and CRB-701, combined with strengthened clinical and business leadership, improves the company’s ability to manage registrational trials and prepare for potential commercialization across multiple programs.
Bears Say
Pre-revenue Business ModelWith no approved products or recurring sales, Corbus lacks operating revenue to fund research and development. Its financial outlook therefore remains dependent on clinical success, licensing proceeds, partnerships, or additional external capital.
Widening LossesThe sharp increase in losses shows that advancing the pipeline is requiring substantially greater spending. Unless clinical progress eventually supports licensing or product revenue, this elevated cost base can continue weakening earnings visibility.
Accelerating Cash BurnRapidly worsening operating cash outflows increase the likelihood that current resources will eventually need to be supplemented. For a pre-revenue biotech, sustained burn raises long-term financing and potential shareholder dilution risk.
Corbus Pharmaceuticals News
CRBP FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was $7.12 and its highest was $20.56 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is $222.04M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Nov 10, 2026 which is in 67 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$1.81 earnings per share for the quarter, missing the consensus estimate of -$1.259 by -$0.551.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.21.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 19,341,293 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.81 in its last earnings report, missing expectations of -$1.259. Following the earnings report the stock price went up 1.776%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Currently, no hedge funds are holding shares in CRBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corbus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.00 (235.99% Upside)
$38.00 (235.99% Upside)
Blogger Sentiment
Bullish
CRBP Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 39.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $126.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
CRBP Stock 12 Month Forecast
Average Price Target
$38.00
▲(235.99% Upside)
Technical Analysis
Ownership Overview
15.09% Insiders
5.07% Mutual Funds
41.40% Other Institutional Investors
28.77% Public Companies and
Individual Investors